Abstract: Embodiments of the invention are directed to systems, methods, and computer program products for automating data validation. The system is configured to receive the initial data set in the first data structure from a network of distributed servers; transform the initial data set into an expected data set having the second data structure using a first mapping logic; use the expected data set to validate a converted data set that was generated by converting the initial data set into the second data structure using a second mapping logic; and transmit control signals configured to cause a user device associated with the user to receive a notification indicating that the match is within the pre-determined tolerance level.

Abstract: The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.

Abstract: Embodiments of the invention are directed to systems, methods, and computer program products for automating data validation. The system is configured to receive the initial data set in the first data structure from a network of distributed servers; transform the initial data set into an expected data set having the second data structure using a first mapping logic; use the expected data set to validate a converted data set that was generated by converting the initial data set into the second data structure using a second mapping logic; and transmit control signals configured to cause a user device associated with the user to receive a notification indicating that the match is within the pre-determined tolerance level.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, decreased insulin production, hyperglycemia, hypoinsulinemia, metabolic syndrome, Type 1 diabetes and obesity, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1? antibody or fragment thereof.

Abstract: An energy absorbing tubular structure is formed of a molded or extruded polymer. The tube has a quadrangular cross-section with rounded corners. The walls of tube are corrugated with alternating convex and concave corrugations surfaces having a continuous constant radius, preferably with no flat spots. The corrugated walls have a constant thickness. The corrugations progressively deform during impact thereby providing a near perfect square wave force vs. deflection energy absorption curve at any predetermined nearly constant force level. The tube may be filled with polymer foam to vary the impact performance of the structure.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.

Abstract: An energy absorbing tubular structure is formed of a molded or extruded polymer. The tube has a quadrangular cross-section with rounded corners. The walls of tube are corrugated with alternating convex and concave corrugations surfaces having a continuous constant radius, preferably with no flat spots. The corrugated walls have a constant thickness. The corrugations progressively deform during impact thereby providing a near perfect square wave force vs. deflection energy absorption curve at any predetermined nearly constant force level. The tube may be filled with polymer foam to vary the impact performance of the structure.

Abstract: The present application relates to a method for enhancing the therapeutic index of a compound that is useful to treat tumors. More specifically, the present invention relates to a method for administering IL-2 to a tumor patient to maximize the therapeutic efficacy and minimize the toxicity.

Abstract: An optical interferometer system is described which precisely measures the angle of rotation of a mirrored surface about a desired axis of rotation without sensitivity to rotation of the surface about an axis perpendicular to the desired axis of measurement. Measurements of the angle or position of a surface are made without attaching any optical or other components to the surface. In operation, a laser beam is passed through a beam splitter which provides two secondary beams. Each of the beams is then passed through a respective optical assembly, each of which is essentially a mirror image of the other. Each of the optical assemblies comprises a unique combination and arrangement of optics which provides a folded optical path wherein the laser beam passes through the system optics and is reflected multiple times by the mirror being measured. Each of the beams then passes back through its respective optical section and is detected by optical means.